PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
In PLOS this week: cancer predisposition among Cowden/Cowden-like and Bannayan-Riley-Ruvalcaba syndrome patients, and more.
In PNAS this week: computational approach combining cancer survival models and machine learning, auxin herbicide resistance mutation, and more.
Working with Case Western Reserve University, the firm will sequence fecal samples from individuals diagnosed with autism and provide results for free to the research community.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
The assay analyzes a digital image of tumor tissue sample to identify ER-positive breast cancer patients who are candidates for adjuvant chemotherapy.
The method detects somatic copy number alterations in whole-exome datasets without requiring input from users and irrespective of sequencing platform.
The tests will use PGT's VeriTag technology in order to detect drug-resistant mutations at the .1 percent level.
University Hospitals' Deepgen HIV assay will use Advanced Biological Laboratories' DeepChek software to help monitor drug resistance and minority variants in HIV strains.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.